Despite of traditional pharmaceutical products that can be fully characterized which are created through a series of chemical processes, biologics are typically proteins and antibodies derived from genetically modified living sources such as bacteria, yeast, or mammalian cells. Since the cell lines in a given source are unique and generate drug products via complex biological systems molecular copies are not identical. Thus the name biosimilars was created for products that are similar, but not identical, to reference biologic agents. Biosimilars require extensive (and expensive) regulatory studies and assessment distinct from those required for generics. With the favoring of large molecules among the market, companies continued investing heavily into the development and commercialization of these molecules.

PHARMANA is expert in consulting biosimilar companies and investors to identify suitable resources in order to develop and optimize their best business model. We work alongside you to help create the foundations for future growth and improve the effectiveness and efficiency of your current businesses.

With disruptive changes altering the basis of competition, MedTech companies may seek new opportunities to redefine business models, enter new markets and deploy their scale advantages in new ways. To thrive in this emerging environment, PHARMANA’s teams of experts help MedTech companies by variety of services in the context of Strategic Consulting, Transaction Advisory, Capital raising and investment.

Because your circumstances or objectives may change, your plans should not be etched in stone. To make it flexible, our advisors work to develop your customized reports, provide ongoing review, and make periodic adjustments or enhancements that directly respond to your changing situation and needs. Transparency and access to information are two main pillars of planning for the future.
To meet these demands PHARMANA provides you series of special studies and services such as: